Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Title | Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. |
Publication Type | Journal Article |
Year of Publication | 2006 |
Authors | Mitsiades, C. S., McMillin D., Kotoula V., Poulaki V., McMullan C., Negri J., Fanourakis G., Tseleni-Balafouta S., Ain K. B., & Mitsiades N. |
Journal | J Clin Endocrinol Metab |
Volume | 91 |
Issue | 10 |
Pagination | 4013-21 |
Date Published | 2006 Oct |
ISSN | 0021-972X |
Keywords | Antineoplastic Agents, Apoptosis, BH3 Interacting Domain Death Agonist Protein, Boronic Acids, Bortezomib, Carcinoma, Carcinoma, Medullary, Caspases, Cell Cycle, Cell Line, Tumor, Cyclin-Dependent Kinase Inhibitor p21, Doxorubicin, Enzyme Inhibitors, Humans, Insulin-Like Growth Factor I, NF-kappa B, Phosphorylation, Proteasome Inhibitors, Proto-Oncogene Proteins c-jun, Pyrazines, Thyroid Neoplasms, Tumor Suppressor Protein p53 |
Abstract | CONTEXT: The ubiquitin-proteasome pathway is a major pathway for degradation of intracellular proteins. Proteasome inhibitors constitute a novel class of antitumor agents with preclinical and clinical evidence of activity against hematological malignancies and solid tumors. The proteasome inhibitor bortezomib (PS-341, Velcade) has been approved by the Food and Drug Administration for the treatment of multiple myeloma and is being studied intensely in several other malignancies. Its mechanism of action is complex but appears to include the inhibition of inhibitory-kappaB degradation, which leads to inactivation of the transcriptional factor nuclear factor-kappaB (NF-kappaB). NF-kappaB has been implicated in the pathophysiology of the most aggressive forms of thyroid carcinoma, i.e. medullary and anaplastic. |
DOI | 10.1210/jc.2005-2472 |
Alternate Journal | J Clin Endocrinol Metab |
PubMed ID | 16849420 |